Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Orphazyme A/S ADR (ORPH)

Orphazyme A/S ADR (ORPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,488
  • Shares Outstanding, K 34,952
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,010 K
  • 60-Month Beta N/A
  • Price/Sales 70.45
  • Price/Cash Flow N/A
  • Price/Book 6.62
Trade ORPH with:

Options Overview Details

View History
  • Implied Volatility 115.09%
  • Historical Volatility 45.36%
  • IV Percentile 1%
  • IV Rank 0.59%
  • IV High 388.46% on 06/17/21
  • IV Low 113.47% on 09/24/21
  • Put/Call Vol Ratio 0.44
  • Today's Volume 734
  • Volume Avg (30-Day) 1,171
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 10,292
  • Open Int (30-Day) 17,647

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -2.13
  • Number of Estimates 1
  • High Estimate -2.13
  • Low Estimate -2.13
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.15 +1.45%
on 09/28/21
5.76 -26.91%
on 08/30/21
-1.12 (-21.01%)
since 08/27/21
3-Month
3.95 +6.58%
on 08/06/21
8.87 -52.54%
on 06/29/21
-3.03 (-41.85%)
since 06/28/21

Most Recent Stories

More News
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

/PRNewswire/ -- , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of...

ORPH : 4.21 (-4.75%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orphazyme A/S (NASDAQ: ORPH), CorMedix...

ORPH : 4.21 (-4.75%)
CRMD : 4.72 (-0.84%)
PHG : 46.09 (+1.07%)
SESN : 0.7800 (-5.21%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain of its officers and directors. The class...

ORPH : 4.21 (-4.75%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH

New York, New York--(Newsfile Corp. - September 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain...

ORPH : 4.21 (-4.75%)
ORPH DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Orphazyme A/S Investors with LOSSES OVER $100K to Secure Counsel Before Important Deadline in Class Action - ORPH

NEW YORK, NY / ACCESSWIRE / August 31, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ:ORPH): (1) pursuant and/or traceable...

ORPH : 4.21 (-4.75%)
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ORPH

/PRNewswire/ --

ORPH : 4.21 (-4.75%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ:ORPH) and certain of its officers...

ORPH : 4.21 (-4.75%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class Action Lawsuit and Upcoming Deadline - ORPH

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain of its officers and directors.  The...

ORPH : 4.21 (-4.75%)
LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action - ORPH

NEW YORK, NY / ACCESSWIRE / August 26, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ:ORPH): (1) pursuant and/or traceable...

ORPH : 4.21 (-4.75%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orphazyme A/S (NASDAQ: ORPH), CorMedix...

ORPH : 4.21 (-4.75%)
CRMD : 4.72 (-0.84%)
PHG : 46.09 (+1.07%)
SESN : 0.7800 (-5.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Orphazyme A/S is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company's product candidate includes Niemann-Pick disease Type C, Amyotrophic Lateral Sclerosis, sporadic Inclusion Body Myositis and Gaucher...

See More

Key Turning Points

3rd Resistance Point 4.64
2nd Resistance Point 4.53
1st Resistance Point 4.37
Last Price 4.21
1st Support Level 4.10
2nd Support Level 3.99
3rd Support Level 3.83

See More

52-Week High 77.77
Fibonacci 61.8% 49.57
Fibonacci 50% 40.86
Fibonacci 38.2% 32.15
Last Price 4.21
52-Week Low 3.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar